Home › Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus
 

Keywords :   


Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus

2016-06-13 16:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Mercks investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-334-4688orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to showing met primary

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
More »